tiprankstipranks
Advertisement
Advertisement
Taysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA
PremiumCompany AnnouncementsTaysha Gene Therapies Ramps Up Ahead of TSHA-102 BLA
1M ago
Whitney Ijem Reiterates Buy Rating and Maintains $17 Price Target on Clinical Momentum and Strong Cash Runway
Premium
Ratings
Whitney Ijem Reiterates Buy Rating and Maintains $17 Price Target on Clinical Momentum and Strong Cash Runway
2M ago
Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)
Premium
The Fly
Taysha Gene Therapies reports Q1 EPS (12c), consensus (10c)
2M ago
Regulatory Clarity and Broad Rett Syndrome Opportunity Drive Taysha Gene Therapies Buy Rating and $10 Target
PremiumRatingsRegulatory Clarity and Broad Rett Syndrome Opportunity Drive Taysha Gene Therapies Buy Rating and $10 Target
6M ago
Taysha Gene Therapies announces progress across TSHA-102
Premium
The Fly
Taysha Gene Therapies announces progress across TSHA-102
6M ago
Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo
Premium
The Fly
Taysha Gene Therapies price target raised to $11 from $8 at Wells Fargo
6M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100